| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_215b60890c623dc2c94ea7bd2afaaf78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ac6dec8eeaa203b95cd9013140c1fc1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e28366cab8a331ef98c86c4b649e4bdb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7023 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-403
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-34 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2012-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a171929d6e6128fd0bc7c61bec092aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9195a3e270bdf569a851beca354d0bc |
| publicationDate |
2013-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013295025-A1 |
| titleOfInvention |
Use of beta-adrenergic inverse agonists for smoking cessation |
| abstract |
The chronic use of p-adrenergic inverse agonists such as nadolol, carvedilol, and ICI-118,551 provides an improved method for the treatment of mucus hypersecretion in subjects with such mucus hypersecretion. One aspect of a method according to the present invention is a method of preventing or controlling mucus hypersecretion in the respiratory tract comprising administering a therapeutically effective quantity of a p-adrenergic inverse agonist to a subject with mucus hypersecretion or at risk of mucus hypersecretion. The invention further encompasses pharmaceutical compositions comprising the p-adrenergic inverse agonist and the additional compound. |
| priorityDate |
2011-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |